A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published on November 7
The Trump administration's landmark deal with major pharmaceutical companies creates a direct pathway to expanded market access. This isn't just market speculation - it's government-backed policy driving real change in healthcare affordability.
For the first time ever, Medicare will cover these highly effective obesity treatments. This opens up a massive, previously untapped patient population that could dramatically boost demand across the entire treatment ecosystem.
While everyone knows about Eli Lilly and Novo Nordisk, this group includes innovative companies developing next-generation oral treatments and complementary therapies. You're getting exposure to the full value chain, not just the obvious players.
The Trump administration's landmark agreement with Eli Lilly and Novo Nordisk to lower GLP-1 drug costs represents a major policy shift. This deal will expand Medicare coverage for obesity treatments for the first time, potentially unlocking a vast, previously untapped market. We believe this catalyst could drive significant growth across the entire obesity treatment ecosystem.
This group includes both established pharmaceutical giants and innovative companies developing next-generation treatments. The selection spans from primary drug manufacturers to specialized suppliers, logistics providers, and companies creating complementary medical devices. The theme captures the full value chain that stands to benefit from increased patient access and affordability.
These companies were handpicked by professional analysts based on their direct exposure to the obesity treatment market expansion. From leading GLP-1 manufacturers like Eli Lilly and Novo Nordisk to emerging biotech firms developing oral alternatives and complementary therapies, each stock offers a strategic position in this growing healthcare sector.
Summary and investor takeaways for the basket based on provided market capitalisation breakdown.
LLY: $886.24B
NVO: $160.22B
GPCR: $1.93B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1
NVO
Current Price
$43.07
The company is a global leader in diabetes and obesity care and a major producer of popular GLP-1 medications, positioning it to gain from increased p...
The company is a global leader in diabetes and obesity care and a major producer of popular GLP-1 medications, positioning it to gain from increased patient access.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+421.52%
On average, analysts expect assets in this group to grow 421.52% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
